Last updated: 3 June 2024 at 4:55pm EST

Johna Norton Net Worth

The estimated Net Worth of Johna Norton is at least $31.3 Milion dollars as of 3 June 2024. Johna Norton owns over 7,056 units of Lilly(Eli) & Co stock worth over $23,416,391 and over the last 7 years he sold LLY stock worth over $7,870,400. In addition, he makes $0 as Senior Vice President - Global Quality at Lilly(Eli) & Co.

Johna Norton LLY stock SEC Form 4 insiders trading

Johna has made over 11 trades of the Lilly(Eli) & Co stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 7,056 units of LLY stock worth $5,781,545 on 3 June 2024.

The largest trade he's ever made was selling 7,056 units of Lilly(Eli) & Co stock on 3 June 2024 worth over $5,781,545. On average, Johna trades about 1,468 units every 121 days since 2018. As of 3 June 2024 he still owns at least 25,428 units of Lilly(Eli) & Co stock.

You can see the complete history of Johna Norton stock trades at the bottom of the page.

Johna Norton biography

Johna Norton is the Senior Vice President - Global Quality at Lilly(Eli) & Co.

How old is Johna Norton?

Johna Norton is 53, he's been the Senior Vice President - Global Quality of Lilly(Eli) & Co since 2017. There are 16 older and 11 younger executives at Lilly(Eli) & Co. The oldest executive at Lilly(Eli) & Co is Kathi Seifert, 71, who is the Independent Director.

What's Johna Norton's mailing address?

Johna's mailing address filed with the SEC is Eli Lilly and Company Corporate Center, Indianapolis, Marion County, Indiana, United States.

Insiders trading at Lilly(Eli) & Co

Over the last 20 years, insiders at Lilly(Eli) & Co have traded over $29,994,829,903 worth of Lilly(Eli) & Co stock and bought 73,808 units worth $5,778,435 . The most active insiders traders include Endowment Inc Lilly, R David Hoover a Lorenzo Tallarigo. On average, Lilly(Eli) & Co executives and independent directors trade stock every 7 days with the average trade being worth of $55,447,708. The most recent stock trade was executed by Endowment Inc Lilly on 3 September 2024, trading 24,084 units of LLY stock currently worth $23,281,762.

What does Lilly(Eli) & Co do?

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War.

Complete history of Johna Norton stock trades at Lilly(Eli) & Co

Osoba	Trans. Transakce	Celková cena
Johna Norton EVP a Global Quality	Prodej	$5,781,545 3 Jun 2024
Johna Norton EVP a Global Quality	Využití opce	$837,425 1 Feb 2024
Johna Norton EVP a Global Quality	Prodej	$1,469,618 14 Jun 2023
Johna Norton EVP a Global Quality	Využití opce	$720,082 1 Feb 2023
Johna Norton EVP a Global Quality	Využití opce	$664,397 1 Feb 2022
Johna Norton EVP a Global Quality	Využití opce	$697,786 1 Feb 2021
Johna Norton EVP a Global Quality	Prodej	$619,237 16 Mar 2020
Johna Norton EVP a Global Quality	Využití opce	$13,689 16 Feb 2020
Johna Norton EVP a Global Quality	Využití opce	$5,879 16 Feb 2019
Johna Norton EVP a Global Quality	Využití opce	$334,448 3 Nov 2018
Johna Norton EVP a Global Quality	Využití opce	$3,791 16 Feb 2018

Lilly(Eli) & Co executives and stock owners

Lilly(Eli) & Co executives and other stock owners filed with the SEC include:

David Ricks,
Chairman of the Board, President, Chief Executive Officer
Joshua Smiley,
Chief Financial Officer, Senior Vice President
Daniel Skovronsky,
Senior Vice President, Chief Scientific Officer and President, Lilly Research Laboratories
David A. Ricks,
Chairman, CEO & Pres
Anat Hakim J.D.,
Sr. VP, Gen. Counsel & Sec.
Jackson Tai,
Independent Director
Juan Luciano,
Lead Independent Director
J. Erik Fyrwald,
Independent Director
Karen Walker,
Independent Director
William Kaelin,
Independent Director
Michael Eskew,
Independent Director
Jamere Jackson,
Independent Director
Katherine Baicker,
Independent Director
Raul Alvarez,
Independent Director
Kathi Seifert,
Independent Director
Marschall Runge,
Independent Director
Carolyn Bertozzi,
Independent Director
Alfonso Zulueta,
Senior Vice President, President - Lilly International
Ilya Yuffa,
Senior Vice President and President of Lilly Bio-Medicines
Anne White,
Senior Vice President, President - Lilly Oncology
Leigh Pusey,
Senior Vice President - Corporate Affairs and Communications
Myles O'Neill,
Senior Vice President and President - Manufacturing Operations
Johna Norton,
Senior Vice President - Global Quality
Michael Mason,
Senior Vice President and President, Lilly Diabetes
Patrik Jonsson,
Senior Vice President, President of Lilly USA , and Chief Customer Officer
Stephen Fry,
Senior Vice President - Human Resources and Diversity
Anat Hakim,
Senior Vice President, General Counsel
Melissa Barnes,
Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Aarti Shah,
Senior Vice President - Chief Information and Digital Officer
Leigh Ann Pusey,
Sr. VP of Corp. Affairs & Communications
Alonzo Weems,
Sr. VP and Chief Ethics & Compliance Officer
Diogo Rau,
Sr. VP & Chief Information and Digital Officer
Kevin Hern,
VP of Investor Relations
Martin Bott MIBS,
VP of Fin. & Special Projects
Donald A. Zakrowski,
Chief Accounting Officer & VP of Fin.
Jacob S. Van Naarden,
Chief Operating Officer of Loxo Oncology
Anat Ashkenazi,
Sr. VP & CFO
Eric Dozier,
EVP, HR & Diversity
Endowment Inc Lilly,
Christi Shaw,
SVP and Pres., Lilly Bio-Meds
Fionnuala M Walsh,
SVP, Global Quality
Jan M Lundberg,
EVP,Science&Tech and Pres. LRL
Maria A Crowe,
President, Mfg. Operations
Ralph Alvarez,
Director
Michael J Harrington,
Senior VP and General Counsel
Jeffrey N Simmons,
SVP&Pres.,Elanco Animal Health
Susan Mahony,
SVP, HR & Diversity
Barton R Peterson,
Sr. VP, Corp. Affairs & Comm.
Derica W Rice,
Sr. Vice President and CFO
Enrique A Conterno,
Sr. VP & Pres., Lilly Diabetes
Naarden Jacob Van,
EVP & Pres., Loxo@Lilly
Donald A Zakrowski,
SVP, Finance, & CAO
Karen N Horn,
Director
John C Lechleiter,
President and COO
Alonzo Weems,
EVP, ERM & CECO
R David Hoover,
Director
Franklyn G Prendergast,
Director
Ellen R Marram,
Director
Douglas R Oberhelman,
Director
Anne Nobles,
Chief Eth/Cmpl Ofcr & SVP, ERM
Bryce D. Carmine,
EVP and Pres, Lilly Bio-Meds
Robert A Armitage,
Sr. VP and General Counsel
Steven M Paul,
EVP, Science and Technology
Frank M Deane,
President, Manufacturing
J Michael Cook,
Director
Alfred G Gilman,
Director
Martin S Feldstein,
Director
Sidney Taurel,
Chairman, President and CEO
Alex M Ii Azar,
Sr. VP, Corp. Affairs & Comm.
Gino Santini,
Sr.VP, Corp. Strategy & Policy
Deirdre P Connelly,
President, Lilly USA
Anthony John Murphy,
Senior VP, Human Resources
Jacques Tapiero,
SVP&Pres., Emerging Markets
Winfried F W Sir Bischoff,
Director
Arnold C Hanish,
Chief Accounting Officer
Lorenzo Tallarigo,
President, Internat'l Opers.
George M C Fisher,
Director
Scott A Canute,
President, Mfg. Operations
Charles E Golden,
Exec. Vice President and CFO
Kimberly H Johnson,
Director
Anat Ashkenazi,
EVP & CFO
Diogo Rau,
EVP & CIDO
Edgardo Hernandez,
EVP & Pres., Mfg. Operations
Gabrielle Sulzberger,
Director
Mary Lynne Hedley,
Director
Melissa Seymour,
EVP, Global Quality